These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7677873)

  • 1. Effect of alfacalcidol on renal bone disease in mild to moderate renal failure. Questions remain over alfacalcidol's efficacy in preventing secondary hyperparathyroidism.
    Fournier A; Esper NE; Moriniere P; Oprisiu R; Marie A
    BMJ; 1995 Jul; 311(6997):124; author reply 124-5. PubMed ID: 7677873
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of renal osteodystrophy in predialysis patients.
    Sanchez CP; Goodman WG; Salusky IB
    Am J Med Sci; 1999 Jun; 317(6):398-404. PubMed ID: 10372840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of alfacalcidol on renal bone disease in mild to moderate renal failure. Monitoring the calcium-phosphate product is important.
    McGregor MS; Rowe PA; Junor BJ
    BMJ; 1995 Jul; 311(6997):124; author reply 124-5. PubMed ID: 7613376
    [No Abstract]   [Full Text] [Related]  

  • 4. Hyperparathyroidism and the predictability of response to 1alpha-hydroxyvitamin D3.
    Bone JM
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():83s-84s. PubMed ID: 606429
    [No Abstract]   [Full Text] [Related]  

  • 5. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
    Madsen S
    Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
    [No Abstract]   [Full Text] [Related]  

  • 6. [Anomalies of phosphorus-calcium metabolism in renal insufficiency. Value of the physiopathological diagnosis and therapy].
    Hioco D; Dorfmann H; Chot ST; Bordier P; de Zèze S
    Rev Rhum Mal Osteoartic; 1972 Oct; 39(10):617-25. PubMed ID: 5083698
    [No Abstract]   [Full Text] [Related]  

  • 7. The management of renal osteodystrophy.
    de Wardener HE; Eastwood JB
    Adv Exp Med Biol; 1977; 81():533-47. PubMed ID: 331902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Progression of hyperparathyroidism during hemodialysis. Response to conservative treatment].
    García de Vinuesa S; Luño J; González C; Resano M; Allés A; Olivas E; Barril G; Valderrábano F
    Rev Clin Esp; 1982 Feb; 164(3):163-7. PubMed ID: 6896386
    [No Abstract]   [Full Text] [Related]  

  • 9. Vitamin D and analogues in renal bone disease and implications for osteoporosis.
    Kanis JA; McCloskey EV; Beneton MN
    Osteoporos Int; 1997; 7 Suppl 3():S179-83. PubMed ID: 9536328
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment with 1-alpha hydroxy vitamin D3 of bone disease in hemodialysis. Therapeutic results and complications].
    García de Vinuesa S; Barril G; Luño J; Alles A; Jofré R; Pérez García R; Olivas E; López Gómez JM; Valderrábano F
    Rev Clin Esp; 1980 Dec; 159(5):317-22. PubMed ID: 7221095
    [No Abstract]   [Full Text] [Related]  

  • 11. The action of 1,25 (OH)2D3 on turnover kinetic, remodelling surfaces and structure of trabecular bone in chronic renal failure.
    Delling G; Lühmann H; Bulla M; Fuchs C; Henning HV; Jansen JL; Kohnle W; Schulz W
    Contrib Nephrol; 1980; 18():105-21. PubMed ID: 7353369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can renal bone disease be prevented?
    Shaldon S
    Proc Eur Dial Transplant Assoc; 1973; 10(0):91-123. PubMed ID: 4808119
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevention of metabolic bone disease in the pre-end-stage renal disease setting.
    Coburn JW; Elangovan L
    J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S71-7. PubMed ID: 11443772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone maturation in children with chronic renal failure. Effect of 1 alpha-hydroxy vitamin D3 and renal transplantation.
    Johannsen A; Nielsen HE; Hansen HE
    Acta Radiol Diagn (Stockh); 1979; 20(1):193-9. PubMed ID: 377915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of intravenous alfacalcidol in the treatment of secondary hyperparathyroidism in patients on hemodialysis.
    González MT; Torregrosa JV; Colomé E; Mendia A; Pavesi M
    Nephron Clin Pract; 2008; 108(2):c141-7. PubMed ID: 18259100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Utilization of alfacalcidol and active vitamin D analogs in chronic kidney disease].
    Ureña-Torres PA; Cozzolino M; Bover J
    Nephrol Ther; 2018 Jun; 14(4):189-200. PubMed ID: 29545131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hyperparathyroidism in chronic renal insufficiency new clinical and surgical aspects (author's transl)].
    Kovarik J; Roka R; Stummvoll HK; Graf H; Niederle P; Woloszczuk W; Wolf A; Pinggera WF; Fritsch A
    Wien Klin Wochenschr; 1981 Oct; 93(20):625-31. PubMed ID: 7324474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of 1 alpha-(OH)D3 on renal osteodystrophy--a 5-year retrospective evaluation].
    Kakuhara T; Mizoguchi M; Itoh M; Nagasawa M; Mori T; Ohtsuka K; Kubota M; Minatoguchi T; Ohara K; Yoshida M; Koide H; Ohno J
    Nihon Jinzo Gakkai Shi; 1982 Jun; 24(6):693-704. PubMed ID: 7176180
    [No Abstract]   [Full Text] [Related]  

  • 19. Improvement of early renal bone disease with alfacalcidol therapy.
    CMAJ; 1995 Nov; 153(10):1470, 1472. PubMed ID: 7585375
    [No Abstract]   [Full Text] [Related]  

  • 20. The use of 1,25-dihydroxyvitamin D3 in early renal failure.
    Goodman WG; Coburn JW
    Annu Rev Med; 1992; 43():227-37. PubMed ID: 1580587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.